

Malaria Chemoprophylaxis during Pregnancy: A Survey of Current Practice amongst Nigerian Obstetricians.

Hyacinth E Onah, Peter O Nkwo and Theophilus O Nwankwo

Department of Obstetrics and Gynaecology, University of Nigeria Teaching Hospital, Enugu, Nigeria.

Abstract

Background: The need for an effective malaria chemoprophylaxis during pregnancy is well established. Sphadoxine-pyrimethamine is the drug currently being recommended by the World Health Organization for such a purpose.

Objective: To determine the current practice of malaria prophylaxis amongst Nigerian obstetricians.

Methods: A questionnaire survey of Nigerian obstetricians who attended the annual conference of the Society of Obstetrics and Gynaecology of Nigeria (SOGON), in Enugu in November 2001.

Results: Ninety-one (60.7%) of the 150 people to whom the questionnaire was administered responded. Seventy-nine (86.8%) of the 91 respondents offered malaria chemoprophylaxis routinely to all their pregnant patients while the remaining 12 (13.2%) did not. The drugs the respondents administered for malaria chemoprophylaxis included chloroquine, pyrimethamine, proguanil, and sulphadoxine-pyrimethamine either singly or in various combinations. The majority of the respondents (31/79 = 39.2%) administered pyrimethamine alone while only 8 (10.1%) respondents administered the sulphadoxine-pyrimethamine currently recommended by the WHO.

Conclusion: The practice of malaria chemoprophylaxis amongst Nigerian obstetricians lags behind current knowledge.

Key Words: Malaria, chemoprophylaxis, pregnancy, practice, Nigerian obstetricians

Introduction

Malaria is currently recognised as the most common and potentially most serious infection occurring in pregnancy in many sub-Saharan African countries¹. The greater susceptibility of pregnant women, especially primigravidae, to malaria is well documented^{2, 3}. As many as half of all primigravidae, have been found to be parasitaemic at the first antenatal visit in some sub-Saharan African countries⁴. Malaria parasitaemia, including subclinical cases are known to cause maternal anaemia, low birth weight and stillbirths⁽⁵⁾. Such resultant low birth weight is reported to be the most important risk factor for neonatal and early infant mortality⁶. Because of these adverse effects of malaria in pregnancy for mother and child, the World Health Organization (WHO) currently recommends a three-pronged approach viz: (a) intermittent preventive treatment (b) insecticide-treated bed nets and (c) case management of malaria illness for malaria prevention and control during pregnancy in malaria endemic areas⁷. Nigeria is an endemic area for malaria. We do not know to what extent this WHO recommendation is being implemented by Nigerian health care providers. Since obstetricians constitute a group that ought to practice the WHO recommendation better than other health professionals, the objective of this study was to determine the current practice of malaria chemoprophylaxis during pregnancy amongst Nigerian obstetricians.

Materials and Methods

A survey of Nigerian obstetricians who attended the annual general meeting of the Society of Obstetrics and

Gynaecology of Nigeria (SOGON) in Enugu, south Eastern Nigeria, was conducted between 28th and 30th November 2001. Data were collected by means of semi-structured self-administered questionnaire. The questionnaire contained questions on respondents' bio-data and their current practices of malaria chemoprophylaxis, including the drugs used and their doses and frequency of administration as well as whether chemoprophylaxis was given to all pregnant women or to primigravidae only. The questionnaires were administered to all consenting participants of the conference. Data analysis was by simple percentages.

Results

A total of 150 questionnaires were administered but 91 questionnaires were completed and returned giving a response rate of 60.7%. The respondents had practised for a mean of 8.2 ± 7.6 (range: 1-34) years. The age distribution of the respondents is shown in Table 1. Sixty-eight (74.8%) of the 91 respondents were aged 31-50 years. The numbers (%) of the respondents from the various geopolitical zones of Nigeria are shown in Table 2. It is noted that the majority of the respondents (38.5%) came from the South East geo-political zone of Nigeria.

Seventy-nine (86.8%) of the respondents offered malaria chemoprophylaxis routinely to all their pregnant patients while the remaining 12 (13.2%) did

Correspondence: Dr. HE Onah, PO Box 3709 General Post Office, Enugu, Nigeria, 400001.

E-mail: hyacinon@yahoo.com

not. The types of malaria chemoprophylaxis offered by the 79 respondents who offered this routinely to their patients are shown in Table 2. All the 79 respondents start the chemoprophylaxis after the first trimester. The doses of the drugs administered and their frequencies were: pyrimethamine 25 mg weekly, chloroquine 500mg weekly, proguanil 100mg daily and sulphadoxine-pyrimethamine 3 tablets monthly. The 79 respondents were asked to estimate the percentage efficacy of the chemoprophylactic antimalarial they used separately for primigravidae and for multiparas. Thirty-five (44.3%) of the 79 respondents said they could not make an estimate while the remaining 44 respondents made an estimate. The mean estimated percentage efficacy of chemoprophylaxis was $55.8 \pm 23.2\%$ (range: 3-90) for primigravidae and $61.6 \pm 25.1\%$ (range: 15-90) for multigravidae. Forty-eight of the 79 respondents reported that the hospitals where they practised had a protocol for malaria chemoprophylaxis while this was not available for the remaining 31 respondents.

Discussion

Earlier attempts at malaria chemoprophylaxis in pregnancy in Nigeria recommended a therapeutic dose of chloroquine 600 mg base to clear the pre-existing malaria followed by pyrimethamine 25 mg weekly as prophylactic⁸. With the emergence of chloroquine resistance in the country, the World Health Organization recommended that the initial therapeutic dose of chloroquine be increased to 1500 mg. In the last two

decades, the efficacy of chloroquine, proguanil and pyrimethamine have diminished markedly as a result of the emergence of multi-resistant strains of *Plasmodium falciparum*⁹⁻¹¹. For this reason, the World Health Organization currently recommends intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine after the first 16 weeks of pregnancy⁷.

The findings in the present study that about one-tenth of Nigerian obstetricians surveyed do not routinely prescribe malaria chemoprophylactic agents during pregnancy and that the majority of them still rely on pyrimethamine, chloroquine and proguanil either singly or in combination, all of which have been shown to be ineffective⁹⁻¹¹ is rather surprising. This might be because of their perceived efficacy of the drugs (56%), which is much lower than the 8 percent documented in randomized controlled trials⁹. It is clear from this study that the practice of malaria chemoprophylaxis among Nigerian obstetricians lags behind current knowledge. Moreover, available data indicate that resistance of malaria parasites to various drugs including the sulphadoxine-pyrimethamine may continue to be a problem in the future¹. Since the issue is dynamic more research needs to be done to evaluate alternatives such as amodiaquine, artesunate, artemether and dapsone either singly or in various combinations. However, clinicians need to apply research results in their clinical practice.

It is concluded that the practice of malaria chemoprophylaxis among Nigerian obstetricians lags behind current knowledge.

Table 1:

(a) The age distribution of the respondents

Age Range (years)	No	Percent
≤ 30	6	6.6
31-40	41	45.1
41-50	27	29.7
51-60	8	8.8
≥ 61	9	9.9
Total	91	100.0

(b) Distribution of the respondents according to the various geo-political regions of Nigeria

Geo-political Area	No	Percent
South East	35	38.5
South West	12	13.2
South South	14	15.4
North Central	10	11.0
North East	11	12.1
North West	9	9.9
Total	91	100.0

Table 2:

Malarial chemo-prophylactic agents used by Nigerian obstetricians

Drug(s) used for prophylaxis	Respondents using drug(s)	
	No	%
Pyrimethamine alone	31	39.2
Proguanil alone	10	12.7
Chloroquine followed by pyrimethamine	6	7.6
Chloroquine alone	8	10.1
Chloroquine followed by Sulphadoxine-pyrimethamine	8	10.1
Pyrimethamine plus proguanil	10	12.7
Sulphadoxine-pyrimethamine followed by pyrimethamine	4	5.1
Chloroquine followed by proguanil	2	2.5
Total	79	100.0

References

1. Newman RD, Parise ME, Slutsker L, Nahlen B, Steketee RW. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programmes in Plasmodium falciparum-endemic in sub-Saharan Africa. *Trop Med Int Health* 2003; 8:488-506.
2. Stekete RW, Nahlen BL, Parise ME et al. The burden of malaria in pregnancy in malaria endemic areas. *Am J Trop Med Hyg* 2001; 64(1-2 Suppl):28-35
3. Scholapurkar SL, Mahajan RC, Gupta AN, Wangoo A. Cellular immunity in pregnant and non-pregnant women with malaria infection. *Asia-Oceania J Obstet Gynaecol* 1990; 16:27-32.
4. Anorlu RL, Odum CM, Essien EE. Asymptomatic malaria parasitaemia in pregnant women at booking in a primary health centre facility in a periurban community in Lagos. *Afr J Med Med Sci* 2001; Suppl: 39-41.
5. Shulman CE, Dorman EK, Bulmer JN. Malaria as a cause of severe anaemia in pregnancy. *Lancet* 2002; 360(9331):494.
6. Luxemburger C, McGready R, Kham A, Morison L, Cho T, Ci T, White NJ, Nosten F. Effects of malaria during pregnancy on infant mortality in an area of low malaria transmission. *Am J Epidemiology* 2001; 154(5) 459-465.
7. World Health Organization. Roll Back Malaria. Malaria in pregnancy. Available at http://www.rbm.who.int/cmc_upload/0/000/015/369/RBMInfoSheet_4.htm Accessed on 29/10/05.
8. Lawson JB. Malaria in pregnancy. In: Lawson JB, Stewart DB (Eds.) *Obstetrics and Gynaecology in the Tropics and Developing Countries*. London: E. Arnold/ELBS 1967:59-72.
9. Iloabachie GC, Onah HE, Nwakoby BAN. Pyrimethamine prophylaxis in pregnancy. *Nig J Surg Sci* 1995; 5:14-17.
10. Ogunbode O, Adeniyi J, Okwerekwu F. Chemoprophylaxis during pregnancy in malaria endemic areas practical considerations. *Trop J Obstet Gynaecol* 1991; 9:31-34.
11. Legge-Ogunoye L. Drug resistant malaria parasites: an update. *Nig J Med* 1991 (Suppl):41-45.